Pembrolizumab for the treatment of renal cell carcinoma-Reference-Cited by-同舟云学术

Pembrolizumab for the treatment of renal cell carcinoma

Published:2021-06-03 Issue:9 Volume:21 Page:1157-1164
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Di Bona Carlo¹,Stühler Viktoria¹,Rausch Steffen¹,Stenzl Arnulf¹,Bedke Jens¹^ORCID

Affiliation:

1. Department of Urology, University of Tübingen, Tuebingen, Germany

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1935856

Reference64 articles.

1. “Kidney and renal pelvis cancer — cancer stat facts.” [Online]. Available: https://seer.cancer.gov/statfacts/html/kidrp.html. [Accessed: 21-Nov-2020].

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer

4. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

5. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis;Annals of Translational Medicine;2022-11

2. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results–Medicare data;Journal of Managed Care & Specialty Pharmacy;2022-10